Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Luminate Medical Limited |
| Country | Ireland |
| Start Date | Oct 01, 2023 |
| End Date | Sep 30, 2025 |
| Duration | 730 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190130710 |
Chemotherapy-induced alopecia (CIA) is hair loss associated with chemotherapy treatment for cancer.
LILY is a portable, comfortable, and effective CIA prevention device that uses localised microvasculature compression therapy (LMCT) to prevent CIA.
The LILY device uses this unique LMCT technique to reduce perfusion at the scalp and prevent the destructive action of chemotherapy on hair follicles.
By applying a consistent low-level pressure (between 35 and 60 mmHg) to the local micro blood vessels, which could deliver chemotherapy drugs to fast-dividing hair follicles, the vessels are temporarily compressed, inhibiting drug delivery.The device comprises a proprietary pneumatic bladder network design and soft robotics system with the ability to non-invasively induce vasoconstriction in superficial vessels of the scalp to mechanically control tissue perfusion, and an electronic control system for both patient management of the system and real-time feedback into the treatment protocol.
Luminate Medical Limited
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant